Merck R&D: A Jam-Packed Pipeline, But Much Of It Is Wait-And-See

With Schering-Plough's research now tucked snugly in with Merck's, the combined company met with analysts and investors for its widely anticipated R&D overview May 11. Even as management laid out a deep mid- to late-stage pipeline especially rich in cardiovascular products, executives provided little in the way of scientific news